{"id":"W4405273291","doi":"10.1182/bloodadvances.2024014903","title":"Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovation Cluster (Canada)","funders":"Cilag; Berlin Institute of Health; Swedish Orphan Biovitrum; Incyte; BeiGene; Agios Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Sanofi; Pfizer; Les Laboratories Pierre Fabre; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Bendamustine; Refractory (planetary science); Cytokine release syndrome; Rituximab; Oncology; Salvage therapy; Gastroenterology; Lymphoma; Surgery; Chemotherapy; Immunotherapy; Cancer; Chimeric antigen receptor; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004057815,0.0005489147,0.0006701033,0.0002529368,0.0003286961,0.0009868668,0.0004708883,0.000707638,0.0008410528],"category_scores_gemma":[0.001675851,0.0002211196,0.0007031799,0.0003435333,0.0006267453,0.000718827,0.0004161504,0.0008140302,0.0003436394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007982297,"about_ca_system_score_gemma":0.000669747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005820273,"about_ca_topic_score_gemma":0.00078877,"domain_scores_codex":[0.9990534,0.0005462978,0.00006791284,0.000138724,0.0001034124,0.00009026124],"domain_scores_gemma":[0.9984375,0.0002597763,0.0006156472,0.0002039918,0.0001278205,0.0003552507],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1438412,0.009880806,0.7662097,0.0002759271,0.001935785,0.0008506828,0.0004732535,0.002060747,0.02135378,0.00009498708,0.001392318,0.05163092],"study_design_scores_gemma":[0.02241911,0.1229217,0.8381042,0.00005106564,0.00136212,0.001894407,0.0002955536,0.003139188,0.005060902,0.0001031206,0.004583682,0.00006500132],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988499,0.0003868527,0.0001124977,0.00006596171,0.000005820638,0.00007983431,0.0002483661,0.00001045422,0.0002403421],"genre_scores_gemma":[0.9985108,0.0001452414,0.0001587934,0.0001334835,0.00001645006,0.00006372289,0.0008620984,0.000004996325,0.0001044287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004057815,"threshold_uncertainty_score":0.02146,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01682718553447772,"score_gpt":0.3415337235392444,"score_spread":0.3247065380047667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}